目的 探讨心脉通胶囊联合盐酸川芎嗪治疗不稳定型心绞痛的临床疗效。方法 选取2013年8月—2016年8月在信阳市第一人民医院进行治疗的不稳定型心绞痛患者178例，根据用药差别分为对照组（89例）和治疗组（89例）。对照组静脉滴注注射用盐酸川芎嗪，80 mg加入5%葡萄糖溶液250 mL，1次/d；治疗组在对照组的基础上口服心脉通胶囊，1.44 g/次，3次/d。两组均经过2周治疗。观察两组患者临床疗效和心电图疗效，比较治疗前后两组患者心绞痛发作次数和持续时间，及血清学指标、血液流变学指标和血脂水平。结果 治疗后，对照组患者临床总有效率和心电图总有效率分别为82.02%、79.78%，均分别显著低于治疗组的95.51%、94.38%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者心绞痛发作次数、持续时间都显著减少（P<0.05）；且治疗组心绞痛发作次数和持续时间明显优于对照组（P<0.05）。治疗后，两组患者髓过氧化物酶（MPO）、白介素-1β（IL-1β）、基质金属蛋白酶-9（MMP-9）、妊娠相关血浆蛋白酶-A（PAPP-A）、血浆黏度（PV）、全血黏度高切（HS）、红细胞聚集指数（EAI）和纤维蛋白原（FIB）水平，及胆固醇（TC）、三酰甘油（TG）和低密度脂蛋白胆固醇（LDL-C）血脂水平均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组患者上述血清学指标、血液流变学指标和血脂水平均明显低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 心脉通胶囊联合盐酸川芎嗪治疗不稳定型心绞痛可显著减少心绞痛发作次数，降低机体炎症反应和血脂水平。

Objective To investigate the clinical efficacy of Xinmaitong Capsules combined with Ligustrazine Hydrochloride for injection in treatment of unstable angina. Methods Patients (178 cases) with unstable angina in the First people's Hospital of Xinyang City from August 2013 to August 2016 were divided into control (89 cases) and treatment (89 cases) groups according to different treatments. Patients in the control group were iv administered with Ligustrazine Hydrochloride for injection, 80 mg added into 5% glucose solution 250 mL, once daily. Patients in the treatment group were po administered with Xinmaitong Capsules on the basis of the control group, 1.44 g/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy and ECG efficacy were evaluated, and the frequency and duration of angina pectoris, serological indexes, hemorheological indexes and blood lipid levels in two groups before and after treatment were compared. Results After treatment, the clinical and ECG efficacy in the control group were 82.02% and 79.78%, which were significantly lower than 95.51% and 94.38% in the treatment group, respectively, and there were differences between two groups (P < 0.05). After treatment, the frequency and duration of angina pectoris in two groups were significantly decreased (P < 0.05). And the improvement of frequency and duration of angina pectoris in the treatment group was significantly better than that in the control group (P < 0.05). After treatment, the MPO, IL-1β, MMP-9, PAPP-A, PV, HS, EAI, FIB, TC, TG and LDL-C levels in two groups were significantly decreased, and there were differences in the same group (P < 0.05). And the serological indexes, hemorheological indexes and blood lipid levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Xinmaitong Capsules combined with Ligustrazine Hydrochloride for injection in treatment of unstable angina can significantly reduce the frequency of angina pectoris, the inflammatory reaction, and blood lipid level.